Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by SpiderRock Advisors LLC

SpiderRock Advisors LLC raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1,442.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 26,917 shares of the company's stock after purchasing an additional 25,172 shares during the period. SpiderRock Advisors LLC's holdings in Moderna were worth $1,799,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company's stock worth $4,159,769,000 after acquiring an additional 5,129,800 shares during the period. International Assets Investment Management LLC boosted its stake in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company's stock worth $21,353,000 after acquiring an additional 316,552 shares during the period. Intech Investment Management LLC lifted its position in shares of Moderna by 1,212.9% in the first quarter. Intech Investment Management LLC now owns 330,805 shares of the company's stock worth $35,251,000 after buying an additional 305,609 shares in the last quarter. Matrix Capital Management Company LP lifted its position in shares of Moderna by 60.8% in the first quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company's stock worth $77,789,000 after buying an additional 276,000 shares in the last quarter. Finally, Motley Fool Wealth Management LLC purchased a new stake in shares of Moderna in the first quarter worth about $21,317,000. Institutional investors own 75.33% of the company's stock.

Moderna Trading Down 6.9 %

Shares of NASDAQ MRNA traded down $3.45 during midday trading on Friday, hitting $46.83. The company's stock had a trading volume of 13,561,538 shares, compared to its average volume of 5,571,917. Moderna, Inc. has a 12-month low of $46.57 and a 12-month high of $170.47. The business's 50 day moving average is $61.85 and its two-hundred day moving average is $99.09. The company has a current ratio of 4.39, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the prior year, the firm earned ($1.39) earnings per share. Moderna's revenue was up 3.8% compared to the same quarter last year. Sell-side analysts expect that Moderna, Inc. will post -9.89 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on MRNA. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research report on Friday. TD Cowen decreased their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a research report on Friday, September 13th. Leerink Partners decreased their price objective on Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a research report on Tuesday, September 17th. Royal Bank of Canada restated a "sector perform" rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Finally, Jefferies Financial Group decreased their price objective on Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research report on Tuesday, October 15th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $93.18.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Moderna news, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,184 shares of company stock valued at $238,531 over the last quarter. 15.70% of the stock is owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.